{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:40:07Z","timestamp":1755852007411,"version":"3.44.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Liver-related abnormalities are commonly observed in patients with congenital heart disease, and these may lead to secondary manifestations such as pruritus. Odevixibat is an ileal bile acid transporter inhibitor under investigation for the treatment of cholestatic liver diseases. Here, we describe the effects of odevixibat treatment in a pediatric patient with congenital heart disease and severe cholestatic pruritus. A 2-year-old male with Kleefstra syndrome, hypoplastic left heart syndrome, and a history of Giessen procedure and biventricular correction surgery presented to the pediatric cardiology and hepatology outpatient clinics at University Children's Hospital Bonn. Portal hypertension was evident on imaging, and the patient was experiencing severe itching attacks that did not respond to treatment with naltrexone, ursodeoxycholic acid, dimetindene, or rifampicin. Sleep and quality of life were poor. Treatment with odevixibat was initiated off label due to refractory pruritus and elevated serum bile acids. Improvements in pruritus and sleep occurred rapidly with odevixibat and were sustained for the duration of treatment. The patient's serum bile acids decreased from 111\u2005\u03bcmol\/L before treatment with odevixibat to 24\u2005\u03bcmol\/L within 1 month of initiating therapy. Relief from pruritus had positive effects on psychomotor development and quality of life. Mild diarrhea lasting 2 days was reported by the patient's mother. In this case report, odevixibat was effective and well tolerated. Together with those of previous studies in patients with progressive familial intrahepatic cholestasis and Alagille syndrome, these results suggest that odevixibat warrants further study as a potential treatment option for patients with cholestatic pruritus of diverse etiologies.<\/jats:p>","DOI":"10.3389\/fped.2024.1443338","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T02:02:06Z","timestamp":1737597726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Odevixibat treatment in a child with hypoplastic left heart syndrome and severe cholestatic pruritus: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Rainer","family":"Ganschow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Maucksch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rauschkolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin B. E.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/17474124.2019.1621746","article-title":"Liver disease secondary to congenital heart disease in children","volume":"13","author":"Komatsu","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0022-5223(19)33989-3","article-title":"Specific sequelae after fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders","volume":"106","author":"Cromme-Dijkhuis","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/hrt.78.2.154","article-title":"Sequelae after modified Fontan operation: postoperative haemodynamic data and organ function","volume":"78","author":"Kaulitz","year":"1997","journal-title":"Heart"},{"key":"B4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00005176-200303000-00009","article-title":"Hepatic dysfunction following the Fontan procedure","volume":"36","author":"Narkewicz","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/hrt.82.1.40","article-title":"Abnormalities in liver function and coagulation profile following the Fontan procedure","volume":"82","author":"van Nieuwenhuizen","year":"1999","journal-title":"Heart"},{"key":"B6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jtcvs.2011.08.038","article-title":"Hepatic pathology may develop before the Fontan operation in children with functional single ventricle: an autopsy study","volume":"143","author":"Schwartz","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.athoracsur.2015.06.071","article-title":"Hepatic abnormalities are present before and early after the Fontan operation","volume":"100","author":"Schwartz","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1017\/S1047951106000291","article-title":"The nomenclature, definition and classification of hypoplastic left heart syndrome","volume":"16","author":"Tchervenkov","year":"2006","journal-title":"Cardiol Young"},{"key":"B9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/archpedi.1970.02100050392002","article-title":"The liver in congenital heart disease. Effects of infantile coarctation of the aorta and the hypoplastic left heart syndrome in infancy","volume":"119","author":"Weinberg","year":"1970","journal-title":"Am J Dis Child"},{"key":"B10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1053\/jhep.2003.50062","article-title":"Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations","volume":"37","author":"Myers","year":"2003","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41575-019-0132-z","article-title":"Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics","volume":"16","author":"Feldman","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/liv.14553","article-title":"Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis","volume":"40","author":"Kamath","year":"2020","journal-title":"Liver Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/bjd.13682","article-title":"The prevalence and characteristics of pruritus in patients with heart failure","volume":"172","author":"Niklasson","year":"2015","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejcnurse.2005.03.010","article-title":"Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure","volume":"4","author":"Zambroski","year":"2005","journal-title":"Eur J Cardiovasc Nurs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"9","author":"Ovchinsky","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100782","DOI":"10.1016\/j.jhepr.2023.100782","article-title":"Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis","volume":"5","author":"Thompson","year":"2023","journal-title":"JHEP Rep"},{"year":"2024","article-title":"Bylvay [summary of product characteristics]. Boulogne-Billancourt, France: Ipsen Pharma","key":"B18"},{"year":"2024","article-title":"Kayfanda [summary of product characteristics]. Boulogne-Billancourt, France: Ipsen Pharma","key":"B19"},{"year":"2024","article-title":"Bylvay [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.","key":"B20"},{"key":"B21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000335648","article-title":"Update on Kleefstra syndrome","volume":"2","author":"Willemsen","year":"2012","journal-title":"Mol Syndromol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/bdra.23324","article-title":"Severe neonatal presentation of kleefstra syndrome in a patient with hypoplastic left heart syndrome and 9q34.3 microdeletion","volume":"100","author":"Campbell","year":"2014","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jjcc.2019.02.016","article-title":"Fontan-associated liver disease: a review","volume":"74","author":"Gordon-Walker","year":"2019","journal-title":"J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1100514","DOI":"10.3389\/fped.2023.1100514","article-title":"Fontan-associated liver disease: diagnosis, surveillance, and management","volume":"11","author":"de Lange","year":"2023","journal-title":"Front Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jtcvs.2004.10.005","article-title":"Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma","volume":"129","author":"Ghaferi","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/MPG.0000000000001958","article-title":"Systematic review: the epidemiology, natural history, and burden of Alagille syndrome","volume":"67","author":"Kamath","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/MPG.0b013e3181ef3771","article-title":"Health status of patients with Alagille syndrome","volume":"51","author":"Elisofon","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hep4.1522","article-title":"Unraveling the relationship between itching, scratch scales, and biomarkers in children with Alagille syndrome","volume":"4","author":"Kamath","year":"2020","journal-title":"Hepatol Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinre.2018.07.010","article-title":"Systematic review of progressive familial intrahepatic cholestasis","volume":"43","author":"Baker","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jceh.2013.10.005","article-title":"Progressive familial intrahepatic cholestasis","volume":"4","author":"Srivastava","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep4.1244","article-title":"Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome","volume":"2","author":"Shneider","year":"2018","journal-title":"Hepatol Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/hep4.1992","article-title":"Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome","volume":"6","author":"Shneider","year":"2022","journal-title":"Hepatol Commun"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1443338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:08:47Z","timestamp":1755850127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1443338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":32,"alternative-id":["10.3389\/fped.2024.1443338"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1443338","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1443338"}}